Navigation Links
Novocure™ Certifies Eight Additional Clinical Centers of Excellence to Treat Most Common Brain Tumor with Tumor Treating Fields (TTFields) Therapy
Date:5/24/2012

PORTSMOUTH, N.H., May 24, 2012 /PRNewswire/ -- Novocure™, a commercial stage private oncology company, announced that by June 1, eight additional clinical centers of excellence will join the seven existing clinical centers that provide Novocure's Tumor Treating Fields (TTFields) therapy to patients with recurrent GBM. These fifteen clinical centers are among the leading cancer centers in the U.S.

GBM is both the deadliest and most common form of primary brain tumor in the U.S., diagnosed in approximately 10,000 Americans each year.  Based on the literature, the median overall survival time from initial diagnosis for patients with GBM is 15 months with optimal treatment, and median survival from the time of tumor recurrence is only 3-5 months without additional effective treatment.  The disease is widely recognized as one of the deadliest forms of cancer.

The NovoTTF-100A™ device was approved by the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of recurrent GBM.  It is available in the U.S. for prescription use from centers whose clinical staff has been trained in the use of the system.

The additional clinical centers and their contacts are:

  • The Cleveland Clinic, Cleveland, Ohio; Dr. Gene H. Barnett
  • Arthur G. James Cancer Center, The Ohio State University, Columbus, Ohio; Dr. Robert Cavaliere
  • The Brain and Spine Tumor Center at USC, Department of Neurosurgery, Los Angeles, CA; Dr. Thomas Chen
  • Fox Chase Cancer Center, Philadelphia, PA; Dr. Tara Morrison
  • University of California, San Francisco (UCSF); Dr. Nicholas Butowski
  • University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Dr. Maciej M. Mrugala
  • Northwestern University, Chicago, IL; Dr. Jeffrey Raizer
  • Geisinger Health System, Danville, PA; Dr. Steven Toms

These eight new clinical centers join the seven existing centers where NovoTTF therapy has been available for recurrent GBM patients since the end of last year:

  • Beth Israel Deaconess Medical Center, Boston, Massachusetts; Dr. Eric T. Wong
  • Mischer Neuroscience Institute in the Memorial Hermann Hospital and The University of Texas Health Science Center, Houston, Texas; Dr. Jay-Jiguang Zhu
  • New Jersey Neuroscience Institute at JFK, Edison, New Jersey; Dr. Joseph Landolfi
  • University of Illinois Hospital, Chicago, Illinois; Dr. Herbert Engelhard
  • NewYork-Presbyterian/Columbia University Medical Center, New York, New York; Dr. Andrew Lassman.
  • Memorial Sloan Kettering Cancer Center, New York, New York; Dr. Lisa DeAngelis
  • University of California San Diego Moores Cancer Center, San Diego, California - Dr. Santosh Kesari

"As we continue to expand the number of clinical centers where NovoTTF therapy is provided, including some of the most prestigious cancer centers in the world, our hope is that more patients can be helped with this effective treatment option which does not have the debilitating side effects seen with traditional chemotherapy," said Gabe Leung, Chairman of Global Commercialization.  "As more physicians gain clinical experience with NovoTTF therapy, we believe it will take its place as a standard of care for this difficult to treat disease."

TTFields therapy, a novel platform technology for the treatment of solid tumors, provides physicians with a fourth treatment modality for recurrent GBM in addition to surgery, radiation therapy and chemotherapy.

TTFields therapy has been shown in vitro and in vivo to effectively inhibit tumor growth by inducing cell death.  TTFields take advantage of the electrical characteristics, geometrical shape and replication rate of dividing cancer cells – all of which makes them susceptible to the effects of alternating electric fields.  The therapy is delivered via non-invasive, insulated transducer arrays that are placed directly on the skin in the region of the tumor.  TTFields therapy is frequency-tuned to target cancer cells and avoid harming normal cells. It creates an artificial, alternating electric field within the tumor which disrupts cancer cell division and can cause complete destruction of the dividing cancer cells.

About the NovoTTF-100A System

The NovoTTF-100A System is a portable, non-invasive medical device designed for continuous use throughout the day by the patient.  The device has been shown in in vitro and in vivo studies to slow and reverse tumor growth by inhibiting mitosis, the process by which cells divide and replicate.  The NovoTTF-100A device, which weighs about six pounds (three kilograms), creates a low intensity, alternating electric field within the tumor that exerts physical forces on electrically charged cellular components, preventing the normal mitotic process and causing cancer cell death prior to division.  In patients with recurrent glioblastoma brain tumors, the device has shown clinical efficacy comparable to that of active chemotherapies with better quality of life and without many of the side effects of chemotherapy.  The most commonly reported side effect from NovoTTF-100A treatment was a mild-to-moderate rash beneath the transducer arrays. The NovoTTF-100A has received marketing approval in the U.S. and is a CE Marked device that is cleared for sale in Europe.

The US Food and Drug Administration (FDA) has approved the NovoTTF-100A System for use as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM), following histologically– or radiologically-confirmed recurrence in the supra-tentorial region of the brain after receiving chemotherapy.  The device is intended to be used as monotherapy, and is intended as an alternative to standard medical therapy for GBM after surgical and radiation options have been exhausted.

Patients should only use the NovoTTF-100A System under the supervision of a physician properly trained in use of the device. Full prescribing information is available at www.novottftherapy.com  or by calling toll free 1-855-281-9301.

About Novocure

Novocure Limited is a private oncology company pioneering a novel therapy for solid tumors.  Novocure's worldwide headquarters is located in the Jersey Isle.  Novocure's U.S. operations are based in Portsmouth, NH and the company's research center is located in Haifa, Israel.  For additional information about the company, please visit www.novocure.com

Media contacts:

Peter Melnyk
Pmelnyk@novocure.com 
(631) 697-7457

Frank Leonard
Fleonard@novocure.com 
(215) 854-4095


'/>"/>
SOURCE Novocure
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Weightlessness weighs heavy on genes a flys perspective
2. LCA-Vision to Present at the Noble Financial Eighth Annual Equity Conference
3. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
4. Dr. Alice Jacobs, CEO of IntelligentMDx, Named Best Entrepreneur in Eighth Annual Stevie® Awards for Women in Business
5. Spherix Announces Results from New Preclinical Studies Showing SPX-106T Produces Significant Reductions in Cholesterol, Fat Deposition and Body Weight
6. Hormone-free hCG Zero Capsules™ Boost Metabolism to Enhance Weight Loss Without Starvation
7. Further Analysis on Improved Genome Assembly Indicates the Outbreak E. coli has Complex Genetics With Resistance to at Least Eight Antibiotics
8. Life Technologies Employees Give Back to Their Communities During Eighth Annual Global Volunteer Day
9. A paperweight for platinum
10. Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression
11. China Sky One Medical Confirms Continued Sale of Seven of Eight Products on the Ministry of Healths Warning List
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... PA (PRWEB) , ... May 02, 2016 , ... ... proud to report on the pre-launch success of their revolutionary, veterinarian-designed product for ... cats to stalk, trap, and play with their food the way nature intended. ...
(Date:4/29/2016)... ... April 30, 2016 , ... The MIT bioLogic design team has won ... explored how bacterial properties can be applied to fabric and formed into living interfaces ... in response to humidity change. The team harvested Natto cells and applied them to ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... medicine, is excited to announce the launch of the Proove Health Foundation ... volunteerism, and education to promote the use of personalized medicine for tackling the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., ... surgical procedures, today announced the completion of a significant transaction and partnership that ... future customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private ...
Breaking Biology Technology:
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):